Cargando…

Failed Degradation of JunB Contributes to Overproduction of Type I Collagen and Development of Dermal Fibrosis in Patients With Systemic Sclerosis

OBJECTIVE: The excessive deposition of extracellular matrix, including type I collagen, is a key aspect in the pathogenesis of connective tissue diseases such as systemic sclerosis (SSc; scleroderma). To further our understanding of the mechanisms governing the dysregulation of type I collagen produ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ponticos, Markella, Papaioannou, Ioannis, Xu, Shiwen, Holmes, Alan M, Khan, Korsa, Denton, Christopher P, Bou-Gharios, George, Abraham, David J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2015
Materias:	Systemic Sclerosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4312903/ https://www.ncbi.nlm.nih.gov/pubmed/25303440 http://dx.doi.org/10.1002/art.38897

Ejemplares similares

STAT3 controls COL1A2 enhancer activation cooperatively with JunB, regulates type I collagen synthesis posttranscriptionally, and is essential for lung myofibroblast differentiation
por: Papaioannou, Ioannis, et al.
Publicado: (2018)

Molecular Basis for Dysregulated Activation of NKX2‐5 in the Vascular Remodeling of Systemic Sclerosis
por: Dritsoula, Athina, et al.
Publicado: (2018)

JunB mediates enhancer/promoter activity of COL1A2 following TGF-β induction
por: Ponticos, Markella, et al.
Publicado: (2009)

Single-cell analysis reveals key differences between early-stage and late-stage systemic sclerosis skin across autoantibody subgroups
por: Clark, Kristina Elizabeth Neergaard, et al.
Publicado: (2023)

Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis
por: Mor, Adi, et al.
Publicado: (2019)

Induced antibodies directed to the angiotensin receptor type 1 provoke skin and lung inflammation, dermal fibrosis and act species overarching
por: Yue, Xiaoyang, et al.
Publicado: (2022)

A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis
por: Allanore, Yannick, et al.
Publicado: (2020)

Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo‐Controlled, Phase II Study
por: Denton, Christopher P., et al.
Publicado: (2017)

Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis
por: Sobanski, Vincent, et al.
Publicado: (2019)

Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort
por: Wu, Wanlong, et al.
Publicado: (2019)

Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis
por: Becker, Mike, et al.
Publicado: (2019)

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression
por: Khanna, Dinesh, et al.
Publicado: (2023)

Nintedanib in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score
por: Kuwana, Masataka, et al.
Publicado: (2022)

Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes
por: Acosta-Herrera, Marialbert, et al.
Publicado: (2021)

A Multicenter Study of the Validity and Reliability of Responses to Hand Cold Challenge as Measured by Laser Speckle Contrast Imaging and Thermography: Outcome Measures for Systemic Sclerosis–Related Raynaud's Phenomenon
por: Wilkinson, Jack D., et al.
Publicado: (2018)

Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial
por: Khanna, Dinesh, et al.
Publicado: (2020)

Targeting human plasmacytoid dendritic cells through BDCA2 prevents skin inflammation and fibrosis in a novel xenotransplant mouse model of scleroderma
por: Ross, Rebecca L, et al.
Publicado: (2021)

Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort
por: Kuster, Simon, et al.
Publicado: (2022)

Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study
por: Cutolo, Maurizio, et al.
Publicado: (2016)

Data on CUX1 isoforms in idiopathic pulmonary fibrosis lung and systemic sclerosis skin tissue sections
por: Ikeda, Tetsurou, et al.
Publicado: (2016)

Transforming growth factor-β-induced CUX1 isoforms are associated with fibrosis in systemic sclerosis lung fibroblasts
por: Ikeda, Tetsurou, et al.
Publicado: (2016)

Boning up on JunB
por: Dove, Alan W.
Publicado: (2004)

Therapeutic and diagnostic outcomes of a standardised, comprehensive care pathway for patients with systemic sclerosis
por: Meijs, Jessica, et al.
Publicado: (2016)

Does the Clinical Context Improve the Reliability of Rheumatologists Grading Digital Ulcers in Systemic Sclerosis?
por: Hughes, M., et al.
Publicado: (2016)

Haematopoietic stem cell transplantation in systemic sclerosis
por: Walker, Ulrich A, et al.
Publicado: (2018)

Overall mortality in combined pulmonary fibrosis and emphysema related to systemic sclerosis
por: Ariani, Alarico, et al.
Publicado: (2019)

Systemic sclerosis: state of the art on clinical practice guidelines
por: Smith, Vanessa, et al.
Publicado: (2018)

Rituximab in early systemic sclerosis
por: Boonstra, Maaike, et al.
Publicado: (2017)

Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2019)

Genome-wide whole blood transcriptome profiling in a large European cohort of systemic sclerosis patients
por: Beretta, Lorenzo, et al.
Publicado: (2020)

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial
por: Seibold, James R, et al.
Publicado: (2020)

Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo‐Controlled Trial in Adults With Systemic Sclerosis
por: Spiera, Robert, et al.
Publicado: (2020)

Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis
por: Kuwana, Masataka, et al.
Publicado: (2020)

Induction of Inflammation and Fibrosis by Semaphorin 4A in Systemic Sclerosis
por: Carvalheiro, Tiago, et al.
Publicado: (2019)

Spontaneous Pulmonary Hypertension Associated With Systemic Sclerosis in P‐Selectin Glycoprotein Ligand 1–Deficient Mice
por: González‐Tajuelo, Rafael, et al.
Publicado: (2020)

Association of antiphospholipid antibodies with active digital ulceration in systemic sclerosis
por: Martin, Mickaël, et al.
Publicado: (2019)

Long non-coding RNA HOTAIR drives EZH2-dependent myofibroblast activation in systemic sclerosis through miRNA 34a-dependent activation of NOTCH
por: Wasson, Christopher W, et al.
Publicado: (2020)

Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis−Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double‐Blind, Placebo‐Controlled Trial
por: Maher, Toby M., et al.
Publicado: (2021)

Anti-centromere antibodies target centromere–kinetochore macrocomplex: a comprehensive autoantigen profiling
por: Kajio, Nobuhiko, et al.
Publicado: (2021)

Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cp5dekhld9m15neqfhvjud4i0a